Cidara Therapeutics Inc (CDTX)
Cidara Therapeutics is a biotechnology company focused on the discovery, development and commercialization of therapeutics designed for patients facing diseases. Co. is focused on infectious diseases and oncology. Co.'s primary product candidate is rezafungin acetate, an intravenous formulation of an echinocandin antifungal. Rezafungin is being developed as a once-weekly therapy for the first-line treatment and prevention of invasive fungal infections. In addition, Co. is using its Cloudbreak® platform to develop a potential new class of drugs called drug-Fc Conjugates, which target respiratory syncytial virus, human immunodeficiency virus, and the SARS-CoV-2 strains causing COVID-19.
| Company Name: |
Cidara Therapeutics Inc |
| Website: |
www.cidara.com |
| Sector: |
Biotechnology |
| Number of ETFs Holding CDTX: |
3 |
| Total Market Value Held by ETFs: |
$2.49M |
| Total Market Capitalization: |
$66.00M |
| % of Market Cap. Held by ETFs: |
3.77% |
|
|
April 18, 2024 • 6:31 PM Eastern
Strong Buy (3.67 out of 4)
100th percentile
|
|
Free CDTX Email Alerts:
